Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 12 for:    ct antigen myeloma
Previous Study | Return to List | Next Study

CT Antigen TCR-Engineered T Cells for Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01892293
Recruitment Status : Terminated (Sponsor Decision)
First Posted : July 4, 2013
Results First Posted : July 24, 2018
Last Update Posted : January 10, 2019
Sponsor:
Information provided by (Responsible Party):
Adaptimmune

Tracking Information
First Submitted Date  ICMJE June 27, 2013
First Posted Date  ICMJE July 4, 2013
Results First Submitted Date  ICMJE March 20, 2018
Results First Posted Date  ICMJE July 24, 2018
Last Update Posted Date January 10, 2019
Actual Study Start Date  ICMJE October 15, 2013
Actual Primary Completion Date December 10, 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 28, 2018)
Adverse Events Related to Study Treatment [ Time Frame: Up to 12 months ]
Number of Participants with NCI CTCAE Version 4.0 Adverse Events related to study treatment greater than or equal to Grade 3
Original Primary Outcome Measures  ICMJE
 (submitted: July 1, 2013)
Safety and Tolerability [ Time Frame: 3 Years ]
Statistical analysis for this study will be primarily descriptive. The evaluable population includes any patient who has received the T cell infusion at the target dose range of ≥1e9-1e10 NY-ESO-1c259-T. For the primary safety endpoints, all adverse events will be described and exact 95% confidence intervals will be produced for adverse event rates, both overall and within major categories.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 28, 2018)
  • Evaluate the Direct Anti-tumor Activity of NY-ESO-1ᶜ²⁵⁹T [ Time Frame: 180 days ]
    Number of participants with response post-infusion as assessed by international uniform response criteria
  • Peak Persistence of Modified T-cells in the Peripheral Blood [ Time Frame: Days 1, 3, 5, 8, 15, 22, 29, 43, 101, 130 181, every 3 months thereafter ]
    Measurement of NY-ESO-1ᶜ²⁵⁹T cells in blood (copies of WPRE per µg of genomic PBMC DNA)
Original Secondary Outcome Measures  ICMJE
 (submitted: July 1, 2013)
Evaluate the direct anti-tumor activity of NY-ESO-1c259-T [ Time Frame: 180 days ]
Analysis of secondary endpoints (e.g., response rate) will be descriptive and may include summary statistics such as means, median, standard deviations, range, and proportions. Confidence intervals will be computed. Endpoints that are taken repeatedly over time will be summarized and plotted against time since infusion to identify patterns over time.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE CT Antigen TCR-Engineered T Cells for Myeloma
Official Title  ICMJE A Phase I/IIa, Open Label, Multiple Site Clinical Trial Evaluating the Safety and Activity of Engineered Autologous T Cells Expressing an Affinity-enhanced TCR Specific for NY-ESO-1 and LAGE-1 in Patients With Relapsed or Progressive Disease in Multiple Myeloma
Brief Summary This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
Detailed Description

The primary objective of the study is to evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A201 patients. Eligibility screening will be performed in two steps. First, patients will undergo prescreening to determine if they have the correct HLA type in order to respond to the engineered T cell therapy, and to test for presence of the target antigen, NY-ESO-1 and LAGE-1, in their tumor cells. Patients, who are HLA-A201 positive and test positive for expression of NY-ESO-1 and/or LAGE-1 in their myeloma tumor will move on to complete all screening procedures to determine eligibility for the study.

Patients will initially undergo a steady-state mononuclear cell apheresis for T cell collection. About 3-4 weeks later (to allow expansion/engineering/releasing the engineered T cells), patients will receive a short course of cytoreductive chemotherapy prior to receiving the engineered T cell infusion, comprised of 1.5 gm/m2 of cyclophosphamide, mesna will be given if in accordance with institutional standards.

At day 0, patients will receive a dose of ≥0.1-1 x 1010 anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express affinity-enhanced NY-ESO-1 T cell receptors (TCRs). A minimum dose of 0.1≤x<1 x 109 will be permitted. Patients receiving this low dose level will be evaluated separately for safety and efficacy.

Patients will undergo myeloma restaging approximately 1 week prior to the T cell infusion, and post infusion at days +28, +42 (week 6), +100 and 6 months post infusion and then every 3 months until relapse/progression or until 1 year, whenever comes first. At this point, patients will be followed semi-annually for up to 5 years and then annually for long term follow-up for monitoring for delayed adverse events until 15 years after receiving the genetically modified T cells, in accordance with FDA Guidelines.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Multiple Myeloma
Intervention  ICMJE Drug: Treatment with NY-ESO-1c259-modified T cells

An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.

For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given.

Study Arms  ICMJE Experimental: Autologous genetically modified T cells
Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
Intervention: Drug: Treatment with NY-ESO-1c259-modified T cells
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: June 28, 2018)
6
Original Estimated Enrollment  ICMJE
 (submitted: July 1, 2013)
10
Actual Study Completion Date  ICMJE April 9, 2018
Actual Primary Completion Date December 10, 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 1. Written informed consent must be obtained from all patients before entry into the study

    2. Patients must have a diagnosis of myeloma (see Appendix A for diagnostic criteria).

    3. Patients must have progressive or active disease following prior therapy for their myeloma which:

    1. includes an IMiD and proteasome inhibitor as separate lines or a combined line of therapy
    2. May include prior auto-SCT but not prior allo-SCT

      Patients who have failed second or third line therapy and beyond, such as DPACE, and who are experiencing a partial response rather than progressive disease are also eligible.

      4. Patients must have measurable disease on study entry. Measurable disease may include quantifiable or detectable levels of serum or urine paraprotein. For patients with minimally secretory disease on study entry, serum free kappa or lambda light chain levels, or the serum free light chain ratio may be measured and used for disease monitoring if abnormal.

      5. Patients must be HLA-A201 as determined by a CLIA certified (or equivalent) clinical laboratory. (This determination will be made under a pre-enrollment screening ICF)

      6. Patients must have confirmed expression of NY-ESO-1 and/or LAGE-1 by RT-PCR, immunohistochemistry or quantigene analysis. (This determination will be made under a pre-enrollment screening ICF)

      Exclusion Criteria:

  • 1. Pregnant or nursing females 2. HIV or HTLV-1/2 seropositivity 3. Known history of myelodysplasia 4. Known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy).

    5. Active Infection with HBV or HCV

    • Active hepatitis B infection as determined by test for hepatitis B surface antigen.
    • Active hepatitis C. Patients will be screened for HCV antibody. If the HCV antibody is positive, a screening HCV RNA by any RT PCR or bDNA assay must be performed at screening by a local laboratory with a CLIA certification or its equivalent. Eligibility will be determined based on a negative screening value. The test is not required if documentation of a negative result of a HCV RNA test performed within 60 days prior to screening is provided.

      6. Prior allogeneic transplant 7. History of severe autoimmune disease requiring steroids or other immunosuppressive treatments.

      8. Active immune-mediated diseases including: connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis.

      9. Evidence or history of other significant cardiac, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease which would likely increase the risks of participating in the study. The specific type of stress test will be selected at the PI's discretion.

      10. Active bacterial or systemic viral or fungal infections.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01892293
Other Study ID Numbers  ICMJE ADP-0011-002
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Adaptimmune
Study Sponsor  ICMJE Adaptimmune
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Edward Stadtmauer, MD University of Pennsylvania
PRS Account Adaptimmune
Verification Date January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP